<DOC>
	<DOC>NCT01162954</DOC>
	<brief_summary>This is a double-blind, randomized, placebo-controlled, 4-period, cross-over clinical trial. The study is designed to evaluate the safety and local tolerability of DA-6034 upon single and repeated-dose topical application to the both eyes in healthy volunteers.</brief_summary>
	<brief_title>Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>2050 yearold healthy subjects Presence or history of dry eye or other ocular or systemic diseases Corrected visual acuity less than 20/40 in either eye at the screening Any eye surgery or laser eye surgery within the past six months Intraocular pressure greater than 22 mmHg in either eye at the screening Breakup time less than 10 sec with OSDI score corresponding to mild to severe dry eye symptoms in either eye at the screening Unanesthetized Schirmer scores &lt;10 mm in either eye at the screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Eye drop, Dry eye</keyword>
</DOC>